1 recruiting, 1 suspended. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Suspended 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Non-Active SPMS: new trials by email Literature Review of Non-Active SPMS trials Research Report on Non-Active SPMS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-10-30 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
Demyelinating Diseases (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1)
Chronic Disease (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Immune System Diseases (1) · Inflammation (1) · Leukoencephalopathies (1) · Nervous System Diseases (1)
Cyclophosphamide (1) · Interleukin-2 (1) · Mesna (1) · aldesleukin (1) · fludarabine (1) · ocrelizumab (1)
Indapta Therapeutics, INC. (1) · Sundance Biosciences, Inc. (1)
United States (2)